NASDAQ : IAM
Iambic Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 13.43 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 636.59M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Iambic Therapeutics, Inc. (IAM) reported revenue of 18.25M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 18.25M | 9.43M | 1.19M |
| Cost of Revenue | 101.74M | 77.53M | 45.70M |
| Gross Profit | -83.49M | -68.10M | -44.50M |
| Selling, General & Admin | 16.69M | 14.25M | 9.38M |
| Operating Expenses | 16.69M | 14.25M | 9.38M |
| Operating Income | -100.19M | -82.35M | -53.88M |
| Interest Expense | -13.00K | -17.00K | -8.00K |
| Interest & Investment Income | 6.07M | 5.21M | 6.04M |
| Other Non Operating Income (Expenses) | -32.00K | -57.00K | |
| EBT Excluding Unusual Items | -94.17M | -77.22M | -47.84M |
| Gain (Loss) on Sale of Assets | -33.00K | -33.00K | |
| Pretax Income | -94.20M | -77.25M | -47.84M |
| Income Tax Expense | 47.00K | 45.00K | 34.00K |
| Net Income | -94.25M | -77.30M | -47.88M |
| Net Income to Common | -94.25M | -77.30M | -47.88M |
| Shares Outstanding (Basic) | 22.07M | 21.62M | 21.42M |
| Shares Outstanding (Diluted) | 22.07M | 21.62M | 21.42M |
| EPS (Basic) | -4.27 | -3.57 | -2.23 |
| EPS (Diluted) | -4.27 | -3.57 | -2.23 |
| Free Cash Flow | -68.17M | -60.10M | -34.27M |
| Free Cash Flow Per Share | -3.09 | -2.78 | -1.60 |
| Operating Margin | -548.93% | -873.65% | -4,512.31% |
| Profit Margin | -516.39% | -820.02% | -4,009.80% |
| Free Cash Flow Margin | -373.50% | -637.63% | -2,869.93% |
| EBITDA | -98.81M | -81.12M | -52.82M |
| D&A For EBITDA | 1.38M | 1.23M | 1.06M |
| EBIT | -100.19M | -82.35M | -53.88M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 207.88M | 180.54M | 141.58M |
| Cash & Short-Term Investments | 207.88M | 180.54M | 141.58M |
| Receivables | 11.61M | 1.32M | 444.00K |
| Prepaid Expenses | 3.41M | 1.73M | 1.84M |
| Total Current Assets | 223.40M | 183.59M | 143.87M |
| Property, Plant & Equipment | 11.13M | 9.85M | 10.52M |
| Other Long-Term Assets | 2.67M | 1.58M | 1.36M |
| Total Assets | 237.20M | 195.02M | 155.75M |
| Accounts Payable | 4.68M | 3.32M | 2.88M |
| Accrued Expenses | 10.70M | 10.08M | 6.31M |
| Current Portion of Leases | 824.00K | 774.00K | 748.00K |
| Current Unearned Revenue | 30.88M | 11.30M | 6.64M |
| Other Current Liabilities | 1.55M | 805.00K | 307.00K |
| Total Current Liabilities | 48.64M | 26.29M | 16.89M |
| Long-Term Leases | 4.40M | 4.88M | 5.75M |
| Long-Term Unearned Revenue | 22.68M | 9.08M | 2.70M |
| Total Liabilities | 75.72M | 40.25M | 25.34M |
| Common Stock | 23.00K | 22.00K | 21.00K |
| Additional Paid-In Capital | 12.68M | 8.57M | 5.61M |
| Retained Earnings | -245.30M | -195.18M | -117.89M |
| Comprehensive Income & Other | 35.00K | 24.00K | 7.00K |
| Total Common Equity | -232.56M | -186.56M | -112.25M |
| Shareholders' Equity | 161.48M | 154.77M | 130.41M |
| Total Liabilities & Equity | 237.20M | 195.02M | 155.75M |
| Total Debt | 5.23M | 5.65M | 6.50M |
| Net Cash (Debt) | 202.65M | 174.89M | 135.08M |
| Net Cash Per Share | 9.18 | 8.09 | 6.31 |
| Filing Date Shares Outstanding | 23.61M | 22.13M | 21.42M |
| Total Common Shares Outstanding | 23.61M | 22.13M | 21.42M |
| Working Capital | 174.76M | 157.30M | 126.98M |
| Book Value Per Share | -9.85 | -8.43 | -5.24 |
| Tangible Book Value | -232.56M | -186.56M | -112.25M |
| Tangible Book Value Per Share | -9.85 | -8.43 | -5.24 |
| Machinery | 10.43M | 8.69M | 7.43M |
| Construction In Progress | 608.00K | 58.00K | |
| Leasehold Improvements | 25.00K | 25.00K | 73.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -94.25M | -77.30M | -47.88M |
| Depreciation & Amortization | 1.38M | 1.23M | 1.06M |
| Loss (Gain) From Sale of Assets | 33.00K | 33.00K | |
| Stock-Based Compensation | 3.78M | 2.48M | 1.65M |
| Other Operating Activities | 1.17M | 1.17M | 1.25M |
| Change in Accounts Receivable | -10.74M | -873.00K | -444.00K |
| Change in Accounts Payable | 891.00K | 441.00K | 280.00K |
| Change in Unearned Revenue | 30.81M | 11.05M | 9.34M |
| Change in Other Net Operating Assets | 1.20M | 2.95M | 1.18M |
| Operating Cash Flow | -65.73M | -58.82M | -33.56M |
| Capital Expenditures | -2.44M | -1.28M | -707.00K |
| Investing Cash Flow | -2.44M | -1.28M | -707.00K |
| Long-Term Debt Repaid | -95.00K | -15.00K | |
| Net Debt Issued (Repaid) | -98.00K | -95.00K | -15.00K |
| Issuance of Common Stock | 2.48M | 484.00K | 37.00K |
| Financing Cash Flow | 153.76M | 99.06M | 64.99M |
| Net Cash Flow | 85.57M | 38.96M | 30.73M |
| Free Cash Flow | -68.17M | -60.10M | -34.27M |
| Free Cash Flow Margin | -373.50% | -637.63% | -2,869.93% |
| Free Cash Flow Per Share | -3.09 | -2.78 | -1.60 |
| Levered Free Cash Flow | -40.44M | ||
| Unlevered Free Cash Flow | -40.43M | ||
| Cash Interest Paid | 14.00K | 17.00K | 5.00K |
| Cash Income Tax Paid | 47.00K | 45.00K | 34.00K |
| Change in Working Capital | 22.16M | 13.57M | 10.36M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 603.89M | ||
| Enterprise Value | 401.23M | ||
| Debt / Equity Ratio | 0.03 | 0.04 | 0.05 |
| Net Debt / Equity Ratio | -1.25 | -1.13 | -1.04 |
| Net Debt / EBITDA Ratio | 2.05 | 2.16 | 2.56 |
| Net Debt / FCF Ratio | 2.97 | 2.91 | 3.94 |
| Asset Turnover | 0.05 | ||
| Quick Ratio | 4.51 | 6.92 | 8.41 |
| Current Ratio | 4.59 | 6.98 | 8.52 |
| Return on Equity (ROE) | -54.21% | ||
| Return on Assets (ROA) | -29.35% | ||
| Return on Capital Employed (ROCE) | -53.10% | -48.80% | -38.80% |
| Buyback Yield / Dilution | -0.93% |